immunotherapy — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T11211	EP4 receptor antagonist 1		Prostaglandin Receptor
	EP4 Receptor Antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist, effective for cancer immunotherapy. It inhibits both human and mouse EP4 receptors with IC50 values of 6.1 nM and...		Prostaglandin Receptor
T7860	SM-324405	SM 324405	TLR
	SM-324405 is an agonist of TLR7.		TLR
T8961	GW280264X	Carbamic acid	MMP
	GW280264X (Carbamic acid) is an inhibitor of ADAM17 .		MMP
T12516	Polyinosinic-polycytidylic acid sodium	Poly(I:C) sodium	Apoptosis , Others , TLR
	Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MD...		Apoptosis , Others , TLR
T4349	Sitravatinib	MG516,MGCD516	Discoidin Domain Receptor (DDR) , VEGFR , FLT , Trk receptor , TAM Receptor , c-Kit , Ephrin Receptor
	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
TP1493L1	PSA1 141-150 acetate	PSA1 141-150 acetate(160215-60-1 free base)	Others
	PSA1 141-150 acetate is used in the immunotherapy of cancer experiments that is a prostate specific antigen 1 peptide.		Others
T40350	HPK1-IN-4	HPK1-IN-4	MAPK
	HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.		MAPK
T77764	DC-Y13-27		Others
	Dc-y13-27, a derivative of DC-Y13, is a potent YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 has antitumor activity that enhances the response of radiotherapy and immunotherapy to tumors.		Others
T69560	ENPP1 inhibitor 43
	ENPP1 inhibitor 43 is a novel small molecule for cancer immunotherapy.
TP2478	WT-1 A1	Tyr-Met-Phe-Pro-agn-Ala-Pro-Tyr-Leu
	WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma.
T61386	CXCR2 antagonist 2
	CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunotherapy with an IC 50 value of 95 nM.
TP1493	PSA1 (141-150)	PSA1 141-150
	This Prostate Specific Antigen 1 peptide was used in the immunotherapy of cancer experiments.
T83135	Alrefimotide	hTERT (660–689)
	Alrefimotide, an immunogenic peptide derived from hTERT, possesses the sequence ALFSVLNYERARRPGLLGASVLGLDDIHRA and has applications in cancer immunotherapy research [1].
T63948	PD-1/PD-L1-IN-16
	PD-1/PD-L1-IN-16 is a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM) and has shown research potential for tumour immunotherapy.
T63458	STING agonist-11
	STING agonist-11 is a potent activator of the small molecule cyclic urea class of STING (EC50: 18 nM).STING activation is a highly promising immunotherapy.
T82348	GAGGVGKSAL
	GAGGVGKSAL, a wild-type KRAS G12D 10mer peptide, serves as an immunogenic neoantigen in cancer immunotherapy research [1].
T82352	GADGVGKSAL
	GADGVGKSAL, a mutant KRAS G12D 10mer peptide, serves as an immunogenic neoantigen in cancer immunotherapy research [1].
T80961	TPPC
	TPPC, a porphyrin-cholesterol conjugate, sensitizes cancer cells to immune checkpoint inhibitors (ICIs) and augments photodynamic immunotherapy in the treatment of lung cancer [1].
T63457	STING agonist-10
	STING agonist-10 is a potent activator of the STING small molecule cyclic urea class (EC50: 2600 nM).STING activation is a highly promising immunotherapy.
T82349	GAGGVGKSA
	GAGGVGKSA, a wild-type KRAS G12D 9mer peptide, serves as an immunogenic neoantigen pivotal for cancer immunotherapy research [1].